Role of tolcapone in the treatment of Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 7, Issue 12, 2007, Pages 1649-1657

  Leegwater Kim, Julie ^a   Waters, Cheryl ^b  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

COMT inhibitor; Motor complications; Parkinson's disease; Tolcapone

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HOMOCYSTEINE; HOMOVANILLIC ACID; LEVODOPA; PERGOLIDE; PLACEBO; TOLCAPONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ENZYME INHIBITION; GLUCURONIDATION; HALLUCINATION; HEADACHE; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MOTOR DYSFUNCTION; MUSCLE CRAMP; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; TABLET FORMULATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINE; VOMITING; XEROSTOMIA;

ANTIPARKINSON AGENTS; BENZOPHENONES; CLINICAL TRIALS AS TOPIC; HUMANS; NITROPHENOLS; PARKINSON DISEASE;

EID: 37149018270     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.12.1649     Document Type: Review

References (61)

1. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535 (2006).
2. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 51, S2-S9 (1998).
3. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39, 889-909 (2003).
4. Block G, Liss C, Reines S et al. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. Eur. Neurol. 37, 23-27 (1997).
5. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 448-458 (2001).
6. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited - clinical features, natural history and mortality. Mov. Disord. 13(6), 885-894 (1998).
7. Chuang C, Waters CH. Initial therapy of Parkinson's disease. In: Office Practice of Neurology (2nd Edition). Samuels M, Feske S (Eds). Churchill Livingstone, PA, USA 743-748 (2003).
8. Pahwa P, Factor SA, Lyons KE et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66, 983-995 (2006). • Important practice parameter for the treatment of motor fluctuations.
9. Guay DR. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy 19, 6-20 (1999).
10. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59, 1233-1250 (2000).
11. Mannisto PT. Clinical potential of catechol-O-methyl-transferase (COMT) inhibitors as adjuvants in Parkinson's disease. CNS Drugs 1, 172-179 (1994).
12. Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen. Pharmacol. 25, 813-824 (1994).
13. Mannisto PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol. Toxicol. 66, 317-323 (1990).
14. Zurcher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Adv. Neurol. 60, 641-647 (1993).
15. 18F]L-DOPA. Eur. J. Pharmacol. 334, 31-38 (1997).
16. 18F-Dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43, 201-207 (2002).
17. Dingemanse J, Jorga K, Schmitt M et al. Integrated pharmacokinetic and pharmacodynamics of the novel catechol-O-methyl-transferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. 57, 508-517 (1995).
18. Dingemanse J, Jorga K, Zurcher G et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur. J. Clin. Pharmacol. 50, 47-55 (1995).
19. Dingemanse J, Jorga K, Zurcher G et al. Pharmacokinetic- pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br. J. Clin. Pharmacol. 40, 253-262 (1995).
20. Limousin P, Pollak P, Pfefen JP et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin. Neuropharmacol. 18, 258-265 (1995).
21. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin. Neuropharmacol. 18, 333-337 (1995).
22. Sedek G, Jorga K, Schmitt M et al. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol. 20, 531-541 (1997).
23. Jorga KM, Sedek G, Fotteler B et al. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther. 62, 300-310 (1997).
24. Yamamoto M, Yokochi M, Kuno S et al. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J. Neural. Transm. 104, 229-236 (1997).
25. Napolitano A, Del Dotto P, Petrozzi L et al. Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease. Clin. Neuropharmacol. 22, 24-29 (1999).
26. Muller T, Woitalla D, Schulz D, Peters S, Kuhn W, Przuntek H. Tolcapone increases maximum concentration of levodopa. J. Neural Transm. 107, 113-119 (2000).
27. Baas H, Zehrden F, Selzer R, Kohnen R, Loetsch J, Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Clin. Pharmacokinet. 40, 383-393 (2001).
28. Jorga KM, Kroodsma JM, Fotteler B et al. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin. Pharmacol. Ther. 63, 646-654 (1998).
29. Jorga KM. COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin. Neuropharmacol. 21, S9-S16 (1998).
30. Kuhn W, Roebroeck R, Blom H et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur. Neurol. 40, 225-227 (1998).
31. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol. Scand. 108, 66-67 (2003).
32. Muller T, Kuhn W. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur. J. Clin. Pharmacol. 62, 447-450 (2006).
33. Lamberti P, Zoccolella S, Iliceto G et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov. Disord. 20, 69-72 (2005).
34. Ostrem JL, Kang JA, Subramanian I et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 64, 1482 (2005).
35. Postuma RB, Espay AJ, Zadikoff C et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled trial. Neurology 66, 1941-1943 (2006).
36. Baas H, Beiske AG, Ghika J et al. Catechol-O-methyl- transferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry 63, 421-428 (1997). • A placebo-controlled trial of the effects of tolcapone in wearing off.
37. Rajput AH, Martin W, Saint-Hilaire M-H et al. Tolcapone improves motor function in parkinsonian patients with the 'wearing-off' phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49, 1066-1071 (1997). • A North American placebo-controlled trial demonstrating the effects of tolcapone on patients with wearing off.
38. Waters CH, Kurth M, Bailey P et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 49, 665-671 (1997). • The first trial of tolcapone in stable patients not yet experiencing wearing off.
39. Dupont E, Burginder JM, Findley LJ et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). Mov. Disord. 12, 928-934 (1997).
40. Suchowersky O, Bailey P, Pourchar E et al. Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin. Neuropharmacol. 24, 214-220 (2001).
41. Tolcapone Study Group. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov. Disord. 14, 38-44 (1999).
42. Koller W, Lees A, Doder M, Hely M; Tolcapone/Pergolide Study Group. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov. Disord. 16, 858-866 (2001).
43. Adler CH, Singer C, O'Brien C et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch. Neurol. 55, 1089-1095 (1998).
44. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neurol. 42, 747-755 (1997). • Randomized placebo controlled trial of entacapone for wearing off.
45. Rinne UK, Larsen JP, Siden A et al. Entacapone enhances the response to levodopa in patients with PD with motor fluctuations. Neurology 51, 1309-1314 (1998).
46. Factor SA, Molho ES, Feustel PJ et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin. Neuropharmacol. 5, 295-299 (2001).
47. Onofrj M, Thomas A, Iacono D et al. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur. Neurol. 46, 11-16 (2001).
48. The Entacapone to Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov. Disord. 22(1), 14-19 (2007). • This trial investigates the efficacy of tolcapone in patients who have been switched from entacapone.
49. Assal F, Spahr L, Hadengue A et al. Tolcapone and fulminant hepatitis. Lancet 352, 958 (1998). • The initial report of tolcapone liver toxicity.
50. New Warnings for Parkinson's Drug Tasmar. US FDA, Rockville, MD, USA, Talk paper T98-T81 (1998).
51. Olanow CW and the Tasmar Advisory Panel. Tolcapone and hepatotoxic effects. Arch. Neurol. 57, 263-267 (2000).
52. Acuna G, Foernzler D, Leong D et al. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. 2, 327-334 (2002).
53. Martignoni M, Cosentino M, Ferrari G et al. Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology 65, 1820-1822 (2005).
54. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 63, 886-891 (2004).
55. Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346, 476-483 (2002).
56. Sasaki T, Watanabe M, Nagai Y et al. Association of plasma homocysteine concentration with atherosclerotic carotid plaques and lacunar infarction. Stroke 33, 1493-1496 (2002).
57. Eikelboom JW, Lonn E, Genest J et al. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med. 131, 363-375 (1999).
58. Bottiglieri T, Laundy M, Crellin R et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J. Neurol. Neurosurg. Psychiatry 69, 228-232 (2000).
59. Lew MF. Tolcapone and the prevention of depression in patients with early-stage Parkinson's disease initiating levodopa. Presented at: 10th International Congress of Parkinson's Disease and Movement Disorders. Kyoto, Japan, 28 October-2 November 2006 (Abstract P1187).
60. Valeant Pharmaceuticals International. Prescribing information for Tasmar (tolcapone) tablets www.tasmar.com
61. European Medicines Evaluation Agency. Tasmar: summary of product characteristics www.emea.eu.int